Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma
- PMID: 38879654
- PMCID: PMC11180102
- DOI: 10.1038/s41598-024-64607-2
Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma
Abstract
This study aimed to compare tumor lesion detectability and diagnostic accuracy of whole-body magnetic resonance imaging (WB-MRI) and radioiodine-labeled meta-iodo-benzylguanidine (mIBG) imaging techniques in patients with metastatic pheochromocytoma and paraganglioma (PPGL). This retrospective study included 13 patients had pheochromocytoma and 5 had paraganglioma, who were all suspected of having metastatic tumors. Each patient underwent WB-MRI and 123I-mIBG as a pretreatment screening for 131I-mIBG therapy. Two expert reviewers evaluated WB-MRI, 123I-mIBG images, and post-therapy 131I-mIBG images for the presence of metastatic lesions in the lungs, bones, liver, lymph nodes, and other organs. Diagnostic measures for detecting metastatic lesions, including sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristics (ROC)-area under the curve (AUC), were calculated for each imaging technique. We analyzed WB-MRI images for detecting metastatic lesions, which demonstrated sensitivity, specificity, accuracy, PPV, NPV, and AUC of 82%, 97%, 90%, 96%, 86%, and 0.92, respectively. These values were 83%, 95%, 89%, 94%, 86%, and 0.90 in 123I-mIBG images and 85%, 92%, 89%, 91%, 87%, and 0.91 in post-therapy 131I-mIBG images, respectively. Our results reveal the comparable diagnostic accuracy of WB-MRI to one of the mIBG images.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11180102/bin/41598_2024_64607_Fig1_HTML.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11180102/bin/41598_2024_64607_Fig2_HTML.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11180102/bin/41598_2024_64607_Fig3_HTML.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11180102/bin/41598_2024_64607_Fig4_HTML.gif)
Similar articles
-
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.Clin Cancer Res. 2021 Jun 1;27(11):2989-2995. doi: 10.1158/1078-0432.CCR-20-3703. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685867 Free PMC article. Review.
-
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.J Natl Cancer Inst. 2012 May 2;104(9):700-8. doi: 10.1093/jnci/djs188. Epub 2012 Apr 18. J Natl Cancer Inst. 2012. PMID: 22517990 Free PMC article.
-
Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma.Clin Nucl Med. 2011 Jan;36(1):1-7. doi: 10.1097/RLU.0b013e3181feeb5e. Clin Nucl Med. 2011. PMID: 21157198
-
Value of 123I-MIBG Scintigraphy in Paraganglioma.Neuroendocrinology. 2010;91(1):94-100. doi: 10.1159/000242499. Epub 2009 Sep 25. Neuroendocrinology. 2010. PMID: 19786729
-
Imaging of pheochromocytoma and paraganglioma.Fam Cancer. 2005;4(1):61-8. doi: 10.1007/s10689-004-2155-y. Fam Cancer. 2005. PMID: 15883712 Review.
References
-
- Wiseman GA, Pacak K, O’Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial. J. Nucl. Med. 2009;50(9):1448–1454. doi: 10.2967/jnumed.108.058701. - DOI - PMC - PubMed
-
- Fukuoka M, Taki J, Mochizuki T, et al. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin. Nucl. Med. 2011;36(1):1–7. doi: 10.1097/RLU.0b013e3181feeb5e. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical